Description
The global self-monitoring blood glucose monitoring devices market was valued at USD 19.8 Billion in 2024, and the market is expected to reach USD 47.5 Billion by 2032, growing at a CAGR of 11.56% from 2025 to 2032. This steady growth is driven by several factors, including the rising global prevalence of diabetes, technological advancements in self-monitoring blood glucose devices in developed countries, and government initiatives aimed at increasing public awareness about diabetes.
Self-monitoring blood glucose devices are medical instruments used by individuals with diabetes to measure and monitor their glucose levels regularly. These devices enable patients to manage their condition effectively by providing real-time data on blood sugar levels, helping them make informed decisions about diet, physical activity, and medication.
The growth of this market is largely driven by the rising global prevalence of diabetes mellitus. According to the International Diabetes Federation (IDF), around 537 million people were living with diabetes worldwide in 2021, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. As diabetes becomes more widespread among patients and healthcare providers, the demand for self-monitoring of blood glucose (SMBG) devices is increasing to support effective disease management.
In addition, government initiatives aimed at improving diabetes awareness and promoting early diagnosis are further supporting market expansion. For example, the U.S. National Diabetes Education Program (NDEP) emphasizes the benefits of SMBG devices in self-management of the disease. Similarly, in the European Union, screening programs focus on high-risk groups such as individuals over 45 years of age and those with a family history of diabetes. These initiatives encourage early detection and timely intervention, which in turn increases the adoption of diabetes care devices to help manage the condition effectively.
Recent Developments
• In April 2025, Dexcom, Inc., received U.S. FDA approval for Dexcom G7 15-Day CGM for people over the age of 18 with diabetes in the U.S. This helped the company to increase its brand presence.
• In November 2024, Ascensia Diabetes Care collaborated with Fitterfly Healthtech to develop a free 21-day Diabetes Management Program offered on Ascensia glucometer devices. It is anticipated that diabetes care will be more effective with this program.
• By Product, the consumables segment dominated the global SMBG market. Self-monitoring blood glucose devices need consumable items such as test strips and lancets for daily diabetes management. These are available over-the-counter, making them easily accessible. In comparison, the self-monitoring blood glucose meters segment was valued at USD XX Billion in 2024, is expected to reach USD XX Billion by 2032. The demand is being driven by rising global prevalence of diabetes (especially type 2), increasing awareness about disease management, and growing adoption of home-based, self-monitoring solutions.
• The primary consumable components are the test strips. Test strips are single-use devices designed to collect blood for glucose measurement. Their small size makes them lightweight, portable, and easy to store. As a result, users can conveniently carry them anywhere and check their blood glucose levels at home, at work, or even while traveling.
• The lancets market was valued at USD XX Billion in 2024, and the market is projected to reach USD XX Billion by 2032. There is a growing preference among patients for self-monitoring at home, for convenience, privacy, and cost savings rather than frequent clinical visits. This increases reliance on SMBG kits , which include lancets. The key players are focusing on better needle designs for lancets, which are blood sample extracting devices, making blood collecting safer and less painful.
• Based on application, the type 2 diabetes emerged as a dominant segment in the market, accounting for 72.5% of revenue share in 2024. Increasing prevalence of this condition is a major reason behind dominance of this segment. according to data from the Centers for Disease Control and Prevention (CDC), Around 38 million individuals in the U.S. are diabetic, and almost 90% – 95% of those cases accounts for type 2 diabetes.
• The type 1 diabetes accounted for xx% share of the total market in 2024, driven by need for intensive, frequent glucose monitoring among type 1 diabetes patients.
• In terms of end users, Homecare accounted for the largest revenue share of xx% in 2024. Self-monitoring blood glucose (SMBG) devices have empowered patients to monitor their blood glucose levels at home instead of visiting a clinic. This improves the self-management of their condition, as it minimizes the need for clinical testing. It is highly beneficial for elderly patients or patients facing mobility challenges because it grants them more control over their health management.
• Hospitals captured second highest share of the total self-monitoring blood glucose monitoring devices market in 2024, largely because they remain central hubs for diabetes diagnosis, acute care, and patient education.
• Diagnostic centers accounted for significant share of the total self-monitoring blood glucose monitoring devices market in 2024, owing to their vital role in routine diabetes screening, follow-up testing, and regular monitoring services. These centers conduct a high volume of fasting glucose tests, oral glucose tolerance tests, and HbA1c assessments, which often lead to recommendations for at-home monitoring, driving demand for SMBG devices. Their accessibility, shorter wait times, and cost-effective testing options attract a large patient base, especially those seeking periodic evaluations outside of hospital settings.
• Based on region, North America dominated the self-monitoring blood glucose monitoring devices market, with the highest market share in 2024. Europe self-monitoring blood glucose monitoring devices accounted for xx% share in 2024, and is anticipated to show lucrative growth over the forecast period. In the European Union, screening campaigns target the high-risk groups, such as people over 45 years of age or those having a family history of diabetes, encouraging early diagnosis and thereby creating demand for diabetes-related treatments.
• The Asia Pacific market for self-monitoring blood glucose devices is witnessing rapid expansion, driven by the increasing prevalence of diabetes, growing health consciousness among the population, and continuous improvements in healthcare infrastructure.
